Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bring on the court battle fda! Stem cell attention and $USRM going WORLD WIDE! Truth going to come out that’s not some PHARMA FAIRY TALE! Wouldn’t miss this one ;). Cheers
$$$USRM
Ding ding. You get it don’t ya fine sir. Yup that’s the game being played here. Creeping tender offer imo which bypasses the 5% rule and to protect themselves they want them as cheap as they can. That’s fine with me too. Keep er down so I can add more. So incredibly cheap here. Imo. Eom
Yes sir!
Phase II/III
The encouraging results led to the design of a multicenter, randomized, double-blind, placebo-controlled phase II/III clinical trial (MARVEL, NCT00526253) in patients (expected n = 390) with class II or III heart failure who had previously experienced MI. Patients were recruited at the time of publication and were to receive MyoCell autologous SkMs (400 or 800 × 106 cells) via injection catheter together with the NOGA XP Cardiac Navigation System [872586], [954700]. The primary endpoints were patient wellbeing and distance they can walk [954700].
Myocell:
Comella states "Patients with treatment did about 100 METERS further in their exercise capacity or 6 min walk test"
"Bi ventricular pacing was APPROVED by the FDA with a 20 METER differential."
"Flag ship product is something that is showing a 5 TIMES greater improvement for what is considered the gold standard for heart failure patients".
Yes. Glad to see it! For the People!
I’m sure it is! Folks that need healing aren’t going to sit around and wait for the corrupt fda. Thanks for the heads up! Oh and to 4school thanks for the movie tip. Never seen it looks good. ;)
$USRM
Future of Medicine ~ $USRM
https://www.google.com/amp/www.thehindu.com/news/cities/mumbai/stem-cell-therapy-gets-rajasthan-boy-back-on-feet/article23963157.ece/amp/
http://kutv.com/features/fresh-living/utah-stem-cells-improve-your-relationship-with-the-o-shot-and-p-shot
https://www.worldhealth.net/news/stem-cell-treatment-aiding-cells-after-heart-attack/
Sometimes, a purchaser or group of purchasers will gradually buy up enough stock to gain a controlling interest (known as a creeping tender offer), without making a public tender offer. This bypasses the Williams Act, but is risky because the target company could discover the takeover and take steps to prevent it.
https://money.howstuffworks.com/hostile-takeover2.htm
https://en.m.wikipedia.org/wiki/Williams_Act
https://corporatefinanceinstitute.com/resources/knowledge/deals/creeping-takeover/
https://www.accountingtools.com/articles/what-is-a-creeping-tender-offer.html
Foot note from a court document regarding USRM. Could this be related?!
https://investorshub.advfn.com/uimage/uploads/2017/2/13/dgsooScreen_Shot_2017-02-13_at_1.58.47_PM.png
Buy and hold. All imo.
$USRM
Agreed. I think it may be a control play right now. Better start payin’ up instead of soakin’! They just might too! Hold tight Cuz ~ I know you will! #NotGettinMineorYours anywhere close to these levels. Imo $USRM
Wow they will have some huge stacks! Love seeing that coming from Camp! Go team $USRM
Bioverativ & Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Dis...
Source: Business Wire
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease. Bioverativ and Sangamo are developing BIVV003 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for sickle cell disease and beta thalassemia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005404/en/
“This acceptance marks the second IND for this gene-editing approach in less than a year, and the first for a gene-edited therapy in sickle cell disease,” said Ken Huttner, M.D. Ph.D., Vice President, Clinical Development at Bioverativ. “It represents our commitment to advancing cutting-edge science and offers hope to the many people who have been waiting generations for an effective way to treat sickle cell disease. We look forward to advancing the program into clinical trials.”
“Sickle cell disease is a lifelong blood disorder with serious, painful and debilitating complications, and patients deserve new, more effective treatment options,” said Ed Conner, M.D., Chief Medical Officer at Sangamo. “Gene-edited cell therapy has the potential to provide patients living with sickle cell disease a lifelong treatment with a single administration. We believe the precision, efficiency and specificity of zinc finger nuclease technology differentiate BIVV003 from other genomic therapies in development.”
BIVV003 is a non-viral approach utilizing zinc finger nuclease (ZFN) gene-editing technology. By modifying a short sequence of the BCL11A gene in a patient’s red blood cell precursors, sickle hemoglobin production is suppressed, and the production of fetal hemoglobin is reactivated to levels that may protect patients against the progression of their sickle cell disease.
This IND enables Bioverativ to initiate a Phase 1/2 clinical trial to assess the safety, tolerability, and efficacy of BIVV003 in adults with sickle cell disease, and Bioverativ expects to open several clinical sites across the United States this year. Currently, Sangamo is enrolling patients with transfusion-dependent beta thalassemia in a Phase 1/2 trial evaluating the safety, tolerability, and efficacy of ST-400, which uses the same gene-editing approach as BIVV003.
About Sickle Cell Disease
Globally, 300,000 people are born with sickle cell disease every year, and approximately 100,000 people are living with sickle cell disease in the United States.1 People with sickle cell disease have a mutation that alters hemoglobin, the protein in red blood cells that carries oxygen to cells throughout the body. The sickle mutation causes red blood cells to have an abnormal sickle or crescent shape, which makes them inefficient in their oxygen-carrying capacity and leads to chronic anemia, vaso-occlusive crises with severe pain, multi-organ damage, complications like stroke, and a shortened life expectancy.
About BIVV003 and the Phase 1/2 Clinical Trial
BIVV003 is an autologous cell therapy that involves gene editing of a patient’s own hematopoietic stem cells (HSCs) using zinc finger nuclease (ZFN) technology. As part of the clinical trial protocol, a patient’s HSCs are isolated from the blood and then undergo non-viral, ex vivo gene editing using ZFNs to modify the erythroid enhancer of the BCL11A gene, which is a key regulator of the level of fetal hemoglobin. Following a bone marrow conditioning regimen, patients are infused with their own modified HSCs, with the goal of producing red blood cells that have increased production of fetal hemoglobin. Using the patient’s own cells reduces the risk of graft failure, and eliminates the risk of graft-versus-host disease and the need for immunosuppression that is associated with transplant from a donor.
About the Bioverativ and Sangamo Collaboration
Bioverativ and Sangamo have an exclusive worldwide collaboration to develop and commercialize ZFN-mediated gene-edited cell therapies for the treatment of beta thalassemia and sickle cell disease. Based on the terms of the agreement, Bioverativ is responsible for conducting the BIVV003 Phase 1/2 clinical trial and subsequent worldwide clinical development, manufacturing, and commercialization.
About Bioverativ, a Sanofi company
Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development, and commercialization of innovative therapies. Bioverativ is committed to actively working with the blood disorders community, and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in hemophilia A and hemophilia B, lysosomal storage disorders MPS I and MPS II, as well as beta thalassemia. Sangamo has an exclusive, global collaboration and license agreement with Kite, a Gilead company, for engineered cell therapies for oncology, with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington’s disease. For more information about Sangamo, visit the Company’s website at www.sangamo.com.
Sangamo’s Forward-Looking Statements
This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the potential for Sangamo’s gene-edited cell therapy to provide patients living with sickle cell disease a long-lasting treatment with a single administration and the potential for the precision, efficiency and specificity of zinc finger nuclease technology to differentiate BIVV003 from other genomic therapies in development. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of the clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo's product candidates, and the reliance on partners and other third-parties to meet their obligations. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s operations and business environments. These risks and uncertainties are described more fully in Sangamo’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
References:
1. World Health Organization; Piel et al. 2013. Lancet 381: 142-51.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005404/en/
Media:
Bioverativ Inc.
Tracy Vineis, +1 781-663-4376
media@bioverativ.com
or
Sangamo Therapeutics, Inc.
McDavid Stilwell, 510-970-6000 x219
mstilwell@sangamo.com
or
Varant Shirvanian, 510-970-6000 x205
vshirvanian@sangamo.com
All great posts Crypto! Nice to read through! Thanks! I slapped a few and sat on a few today. A few times those MM’s were hiding my bids. A lot of room to run up here. Glad I grabbed a few more! $USRM
Buy em up! ;)
IT’S COMING! :
New Silicon Valley Trend: Freeze Your Stem Cells For $7K
Forever Labs in California is getting a lot of business from tech workers who want to extend their lifespan down the line by freezing their stem cells for $7,000 a shot. Good to know a guy who wrote some code for Candy Crush will outlive the rest of us.
http://theinterrobang.com/new-silicon-valley-trend-freeze-stem-cells-7k/
Yeah the guy with 17 medical patents. Businesses bought by amazon and j and j. And Comella one Of the top stem cell scientists in the world and Has been part of 10,000+ procedures with very few adverse events. LOLOLOLOLOLOLOL CHEERS
Tellin’ you be careful who you trust. Do your own DD. I’ll go with Dr. Murphy Comella and team. Future of meds! $$USRM
LOL LOL LOL BUY EM UP! ;)
Oh..gotcha thanks
How do you know it’s not being sold now? In an 8-k it says they were expecting to start selling Jan 2018.
https://backend.otcmarkets.com/otcapi/company/sec-filings/12316110/content/html
FutureLand Corp. (FUTL) announced today that on October 05, 2017, the Company has started its first harvest at Groovy Groves location in Oregon. The harvest will be in stages and will continue until all plants have been harvested. We are very excited at this momentous occasion for the Company and its shareholders. The proceed of this first harvest will be used to reduce our operating losses and debts. We will continue to expand our harvest and yields in the coming crops and locations in Oregon through larger cultivation areas and greenhouse or indoor facilities.
https://www.facebook.com/futurelandcorp/posts/1708253132573437
https://www.facebook.com/futurelandcorp/videos/1602764519788966/
https://www.facebook.com/futurelandcorp/videos/1601854389879979/
https://www.otcmarkets.com/stock/FUTL/overview
https://backend.otcmarkets.com/otcapi/company/sec-filings/12610063/content/html
I’m not saying that this company has done everything right that is for sure. Just saying that it is not a shell by my DD. They seem to be filling their pipeline and 2018 MAY be the turning point for the company. Looking forward to seeing what the coming Q looks like. Imo
Nice job jumpin the c boyz oh they don’t like that.
SELL NONE!! Sit in front of cdel and cant LOL
What do you know..CANT sittin’ like always tryin’ to soak up as many as they can. USRM shares must be very desirable and way undervalued?!?! ;) BUY EM UP!
Grabbed some shares before the Mj mania begins. I feel like this one could be a big runner at this low pps. Glta
GREAT PR! USRM THE SAINT & PHARMA/FDA THE SINNER! NOW THAT’S THE TRUTH! FIGHT FOR THE PEOPLE! MY CELLS I CAN DO WHAT I WANT WITH THEM! $$USRM
https://americanstemcell.com
These clinics with more to come will provide huge revs for USRM imo!
Plus I hear Comella inviting folks to give her a call. Listen to Comella not to people on here imo.
$USRM
Have you seen the pics of the Miami clinic?! State of the art and beautiful! Hope they are all replicated that way!
Exactly. Plus the partner clinics throughout the country are just starting to open with more coming. Revs haven’t even been reflected from those streams yet. $USRM
Yup there are desperate patients and it literally should be a crime that they are trying to slow it down. Safe and effective technology! 10000 plus patients with very few adverse events! AMAZING RESULTS!!
THEY WILL NOT BE ABLE TO STOP STEM CELL THERAPY FROM COMING FORWARD IN THE US! They know that though so they try to slow it down and protect their bottom line. Insurance companies will eventually be on board too. To wide spread around the world and in the USA already! USRM is the FACE OF REGENERATIVE MEDICINE so they try to pick on us in the mean time. The story will be told on a bigger level. THE REAL STORY! Not the big pharma/fda/paid journalist Negative try to scare BS. The REAL STORY will attract more money and influence. Go on main stream media and do talks shows if that what it takes! Imo just get the good word out faster and do what it takes USRM. With a lawsuit I’m sure it will do that though!! Let the world know about this lil ole penny stock and the amazing tech! ;))!! 500 shareholders to a 100000 shareholders?!?!? Buy em up! Happy to have a front row seat for this one! All imo. FOR THE PEOPLE!!
$GO USRM
http://usstemcellclinic.com/testimonials/
Joe Rogan Experience~ Mel Gibson on his dad getting stem cells
What do you know CANT sittin’ there like always trying to suck up shares. Surprise surprise.:p buy em up.
Could the “puppet master” be big pharma?! Are they behind the scenes loading the boat on many front runner regenerative medicine stocks and protecting their market share?! Very good chance imo.
Agree with deceptive involvement. I think they are loading as many as they can along the way. Only can load as many as they can get. Oh if they could get 100 milly shares here they would. imo. #Notforsale
$USRM
Everyone wants shares. PERIOD! Some are just more pathetic and greedy about it. Same story different day. Buy em up.
Great posts gobsmacked,stubborn, NoMo and 4school! I’ll be grabbing more today.
I added some today at .028 J. Rough day obviously. RSI is sure in the gutter now. Didn’t sell here before and won’t now. No more pm for me. I hope the publicity spreads world wide and in a big way! We may then get some big money that comes in and rips shit UP! This may be the exposer we needed bad or good at first because in the end I believe the people will see through pharmas and fda greed. Let the story be told world wide to the people! Bring it on! There have been deep pockets loading as many as they can since I’ve been here. If they get competition for the shares look out because she will fly imo(read the CO article below). Holding long because I believe in the tech and Usrm succeeding. “someone” with deep pockets does too! I thought Comellas interview was great today! All imo. $USRM
http://www.cbs8.com/story/38158368/usrm-chief-science-officer-dr-kristin-comella-featured-on-health-boot-camps-webinar
http://stockcharts.com/articles/wyckoff/2015/06/accumulation-phase-absorbing-stock-like-a-sponge.html
http://business.financialpost.com/investing/the-secret-trading-strategy-from-the-1930s-that-hedge-funders-dont-want-you-to-know-about
WE THE PEOPLE!!!
http://usstemcellclinic.com/testimonials/
Joe Rogan Experience~ Mel Gibson on his dad getting stem cells
Nope. Regenerative medicine is the future.
$$USRM
Exactly! Many more revenue streams than just the sunrise! If anything I hope that MILLIONS see the news!!! I hope EVERY NEWS CHANNEL IN THE WORLD puts it on!! Let’s let the PEOPLE DECIDE!! This lil ole PENNY STOCK could go PARABOLIC! I’ll continue to add! $USRM
USRM Will Vigorously Defend Medical Freedom of Americans
SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U.S. Department of Justice at the request of the U.S. Food and Drug Administration (FDA). The lawsuit seeks to stop US Stem Cell Clinic and related parties from performing a surgical procedure using stem cells from autologous adipose tissue, even when a physician and patient agree that such a procedure is in the best interest of the patient. USRM believes that the patient and physician have the right to decide whether or not to use a patient’s own cells for a therapeutic purpose without federal government interference.
U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead, developmental product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.
Yup this lil penny stock is sure shaking things up. So many folks hate the fda and big pharma and will see through their BS just like we do. Will bring so many new eyes in our favor imo. The Usrm crew will fight for what’s right imo!